Table 2. Relative Risk of Cardiovascular Events in Patients With Psoriasis and Psoriatic Arthritis Treated With Ustekinumab vs TNFi.
| Outcome, Data Source | Ustekinumab | TNFi | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, No. | Events, No. | Person-Years, No. | IR per 1000 Person-Years (95% CI) | IR Ratio (95% CI) | Patients, No. | Events, No. | Person-Years, No. | IR per 1000 Person-Years (95% CI) | IR Ratio | |
| Unadjusted | ||||||||||
| Atrial fibrillation | ||||||||||
| Optum | 2733 | 17 | 3382 | 5.0 (3.0-7.9) | 1.24 (0.73-2.11) | 12 737 | 68 | 16 806 | 4.1 (3.2-5.1) | 1 [Reference] |
| MarketScan | 6338 | 43 | 8545 | 5.0 (3.7-6.7) | 1.03 (0.75-1.43) | 38 220 | 255 | 52 514 | 4.9 (4.3-5.5) | 1 [Reference] |
| MACEa | ||||||||||
| Optum | 2733 | 13 | 3397 | 3.8 (2.1-6.4) | 0.71 (0.40-1.27) | 12 737 | 90 | 16 748 | 5.4 (4.3-6.6) | 1 [Reference] |
| MarketScan | 6338 | 61 | 8531 | 7.2 (5.5-9.1) | 1.13 (0.86-1.49) | 38 220 | 331 | 52 435 | 6.3 (5.7-7.0) | 1 [Reference] |
| Adjusted for Propensity Score | ||||||||||
| Atrial fibrillation | ||||||||||
| Optum | 2730 | 17 | 3379 | 5.0 (3.0-7.9) | 1.40 (0.81-2.41) | 12 673 | 55 | 15 272 | 3.6 (2.7-4.7) | 1 [Reference] |
| MarketScan | 6336 | 43 | 8545 | 5.0 (3.7-6.7) | 0.96 (0.70-1.33) | 37 996 | 258 | 49 268 | 5.2 (4.6-5.9) | 1 [Reference] |
| MACEa | ||||||||||
| Optum | 2730 | 13 | 3393 | 3.8 (2.2-6.4) | 0.83 (0.46-1.51) | 12 673 | 70 | 15 228 | 4.6 (3.6-5.8) | 1 [Reference] |
| MarketScan | 6336 | 61 | 8531 | 7.2 (5.5-9.1) | 1.22 (0.92-1.61) | 37 996 | 289 | 49 229 | 5.9 (5.2-6.6) | 1 [Reference] |
Abbreviations: IR, incidence rate; MACE, major adverse cardiovascular event; TNFi, tumor necrosis factor inhibitor.
a
Composite cardiovascular event of myocardial infarction, stroke, and coronary revascularization.